Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good green closure!
Closing green
GOOD QUOTE: The First Sign of Cardiovascular Disease is Often an Unannounced Heart Attack!
• Current first line cardiovascular health
diagnostics are insensitive at measuring
heart disease development and
progression
• Specialized cardiovascular diagnostics
are highly invasive and expensive and
generally catch cardiovascular disease
AFTER it’s developed
...we need a simple way to proactively measure and monitor
cardiovascular system health BEFORE the development of heart disease
SUMMARY LXGTF : Lexington BioSciences (CSE: LNB) (OTCQB: LXGTF) is developing the HeartSentry, a new non-invasive diagnostic tool for accurately measuring and monitoring cardiovascular health.
• The HeartSentry measures the function of the endothelium – the critical inner lining of a person’s cardiovascular system.
• The core research and IP portfolio has been exclusively licensed to the company.
• Lexington is in final stages of releasing the product into clinical studies for FDA approval.
• The cardiovascular diagnostic market is growing fast and evolving into
personalized medicine.
• The goal is to make HeartSentry the standard of care for cardiologists, general
practitioners, and ultimately patients first line evaluation of cardiovascular health.
• We seek the participation of dedicated stakeholders and committed
partners who share our vision of the future of cardiovascular personalized medicine.
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person's vascular endothelium - the vital innermost lining of a person's cardiovascular system. Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician. The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in portfolio of multiple pending and issued patents licensed to the company. By taking delivery of the clinical trial ready HeartSentry units the company will commence studies as soon as possible. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person's cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit:
https://lexingtonbiosciences.com/.
Eric Willis
CEO & Director
wow it was there
Power Hour entrance!
Awasome
FDA timing...
still stable before the power hour!
Amazing LXGTF article Mike! Tnx
wow yesss LXGTF is Great!
Adama Technologies Corp. has been analyzing the market base for identity theft protection products and services and has establishing the long term strategy for marketing and customer engagement. To-date approximately 12% of consumers pay for an Identity Protection Subscription Service, and businesses that acquire protection is significantly less; indicating a huge untapped market. Victims of Identity theft and fraud related issues suffered more than $16 billion in direct and indirect losses in 2016 -- that's more than the combined $14 billion in losses consumers experienced from other types of theft (burglary, motor vehicle theft and other property theft) in the same period.
Absolutely Italian!
the accumulations is here yes, we going forward
great news Mike!
hahaha I like to make it on my own, spirit of adventure :)
we need some more volume
THE POINT!: Blood pressure monitor market forecast to exceed $2.6 billion by 2020
ANOTHER TRUTH! : LXGTF simplify and save lifes!!! Current Standards are Complicated and Expensive!!!
• Gold standard - ULTRASOUND
• Measurement directly views arterial diameter
changes
• Only at specialized diagnostic centers
• Requires trained ultrasonographer
• Expensive capital equipment needed
• Alternative method - ENDOPAT
• Measurement uses a fingertip blood oxygen
sensor and laptop computer.
• Only at specialized diagnostic centers
• Requires trained technician
Currently only used in specialized research centers by highly trained staff
STEP BEFORE OTHERS! Endothelial function measurement predicts when arteries are vulnerable to developing atherosclerosis
SAW IT? : LXGTF is potential 50 Billion Dollar Industry Penny Stock to Watch!
Read More here:
https://t.co/4nL5f2LtnQ
ADAC is an interesting opportunity to watch!
LXGTF is potential 50 Billion Dollar Industry Penny Stock to Watch!
Read More here:
https://t.co/4nL5f2LtnQ
LXGTF is a great opportunity, a 50 Billion market
LXGTF started green and firmly .47
INFORMATION PROTECTION IS SO IMPORTANT: The Wall Street Journal has reported that 60% of businesses that suffer business identity fraud close their doors within 1 year. To combat this serious issue and protect the assets that small business owners have worked their lifetime to accumulate, SafeGuard offers affordable, effective solutions specifically designed for small to midsized businesses, to business owners."
Interesting! Adama plans to introduce a powerful solution into the market and will offer Identity Theft Protection Programs as an employee benefit to corporate clients and has already secured three corporate contracts with more than 100 employees already enrolled in the benefit program. Mark Brown, Director and Lead Executive of SafeGuard, has more than 25 years of experience in data security and management.
Hello everybody!
stable .47 green
Check about Dr. Maltz from the management team! : https://lexingtonbiosciences.com/company/management/
HAVE YOU SEEN RECENTLY RELEASED ARTICLE?
https://insiderfinancial.com/lexington-bioscien-otcmktslxgtf-venturing-into-fortune-500-territory
Check the LXGTF Management Team here: https://lexingtonbiosciences.com/company/management/
LXGTF is a "Breakthrough technology" In LXGTF HeartSentry you have a simple, affordable, portable device that requires no expert training to use and yet by measuring endothelial function it can knock the wind out of the diseases that cause 25% of ALL deaths in the modern world (heart disease and stroke)Its only competition area devices that cost up to six figures, can fill a small room and require medical training to operate.
START YOUR DD FROM THE WEB PAGE AND AMAZING VIDEO HERE:
https://lexingtonbiosciences.com/
https://vimeo.com/183611304
Green .47 early morning, how amazing is to start in that way!
Good morning everybody!
tomorrow will be a better day, I wish you a good evening!
yes some unanswered questions...